Literature DB >> 18691045

Protein kinase CK2 in human diseases.

Barbara Guerra1, Olaf-Georg Issinger.   

Abstract

Protein kinase CK2 (formerly referred to as casein kinase II) is an evolutionary conserved, ubiquitous protein kinase. There are two paralog catalytic subunits, i.e. alpha (A1) and alpha' (A2). The alpha and alpha' subunits are linked to two beta subunits to produce a heterotetrameric structure. The catalytic alpha subunits are distantly related to the CMGC subfamily of kinases, such as the Cdk kinases. There are some peculiarities associated with protein kinase CK2, which are not found with most other protein kinases: (i) the enzyme is constitutively active, (ii) it can use ATP and GTP and (iii) it is found elevated in most tumors investigated and rapidly proliferating tissues. With the elucidation of the structure of the catalytic subunit, it was possible to explain why the enzyme is constitutively active [1] and why it can bind GTP [2]. Considerable information on the potential roles of CK2 in various disease processes including cancer has been gained in recent years, and the present review may help to further elucidate its aberrant role in many disease states. Its peculiar structural features [3-9] may be advantageous in designing tailor-made compounds with the possibility to specifically target this protein kinase [10]. Since not all the aspects of what has been published on CK2 can be covered in this review, we would like to recommend the following reviews; (i) for general information on CK2 [11-18] and (ii) with a focus on aberrant CK2 [19-22].

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18691045     DOI: 10.2174/092986708785132933

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  85 in total

Review 1.  Emergence of protein kinase CK2 as a key target in cancer therapy.

Authors:  Janeen H Trembley; Zhong Chen; Gretchen Unger; Joel Slaton; Betsy T Kren; Carter Van Waes; Khalil Ahmed
Journal:  Biofactors       Date:  2010 May-Jun       Impact factor: 6.113

2.  ck2-dependent phosphorylation of progesterone receptors (PR) on Ser81 regulates PR-B isoform-specific target gene expression in breast cancer cells.

Authors:  Christy R Hagan; Tarah M Regan; Gwen E Dressing; Carol A Lange
Journal:  Mol Cell Biol       Date:  2011-04-25       Impact factor: 4.272

3.  CK2 modulation of NF-kappaB, TP53, and the malignant phenotype in head and neck cancer by anti-CK2 oligonucleotides in vitro or in vivo via sub-50-nm nanocapsules.

Authors:  Matthew S Brown; Oumou T Diallo; Michael Hu; Reza Ehsanian; Xinping Yang; Pattatheyil Arun; Hai Lu; Vicci Korman; Gretchen Unger; Khalil Ahmed; Carter Van Waes; Zhong Chen
Journal:  Clin Cancer Res       Date:  2010-04-06       Impact factor: 12.531

4.  Examination of CK2α and NF-κB p65 expression in human benign prostatic hyperplasia and prostate cancer tissues.

Authors:  Fatima Qaiser; Janeen H Trembley; Sarah Sadiq; Iqbal Muhammad; Rubina Younis; Shoaib Naiyar Hashmi; Badar Murtaza; Thomas S Rector; Abdul Khaliq Naveed; Khalil Ahmed
Journal:  Mol Cell Biochem       Date:  2016-07-19       Impact factor: 3.396

5.  Role of polyamines in determining the cellular response to chemotherapeutic agents: modulation of protein kinase CK2 expression and activity.

Authors:  Jan N Kreutzer; Birgitte B Olsen; Karolina Lech; Olaf-Georg Issinger; Barbara Guerra
Journal:  Mol Cell Biochem       Date:  2011-07-13       Impact factor: 3.396

6.  Identification of novel CK2 inhibitors with a benzofuran scaffold by novel non-radiometric in vitro assays.

Authors:  Andreas Gratz; Uwe Kuckländer; Ricardo Bollig; Claudia Götz; Joachim Jose
Journal:  Mol Cell Biochem       Date:  2011-07-13       Impact factor: 3.396

7.  Lack of the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs) is accompanied by increased CK2α' levels.

Authors:  Birgitte B Olsen; Ulrike Fischer; Tine L Rasmussen; Matthias Montenarh; Eckart Meese; Gerhard Fritz; Olaf-Georg Issinger
Journal:  Mol Cell Biochem       Date:  2011-07-13       Impact factor: 3.396

8.  Dihydrobenzo[4,5]imidazo[1,2-a]pyrimidine-4-ones as a new class of CK2 inhibitors.

Authors:  Mykola V Protopopov; Olga V Ostrynska; Sergiy A Starosyla; Maria A Vodolazhenko; Svetlana M Sirko; Nikolay Yu Gorobets; Volodymyr Bdzhola; Sergey M Desenko; Sergiy M Yarmoluk
Journal:  Mol Divers       Date:  2018-05-29       Impact factor: 2.943

9.  Differential phosphorylation of a regulatory subunit of protein kinase CK2 by target of rapamycin complex 1 signaling and the Cdc-like kinase Kns1.

Authors:  Manuel E Sanchez-Casalongue; Jaehoon Lee; Aviva Diamond; Scott Shuldiner; Robyn D Moir; Ian M Willis
Journal:  J Biol Chem       Date:  2015-01-28       Impact factor: 5.157

10.  Enhancing chemosensitivity to gemcitabine via RNA interference targeting the catalytic subunits of protein kinase CK2 in human pancreatic cancer cells.

Authors:  Jan N Kreutzer; Maria Ruzzene; Barbara Guerra
Journal:  BMC Cancer       Date:  2010-08-19       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.